[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1124024T1 - Νεες ctla4-ig ανοσοπροσκολλητινες - Google Patents

Νεες ctla4-ig ανοσοπροσκολλητινες

Info

Publication number
CY1124024T1
CY1124024T1 CY20201100987T CY201100987T CY1124024T1 CY 1124024 T1 CY1124024 T1 CY 1124024T1 CY 20201100987 T CY20201100987 T CY 20201100987T CY 201100987 T CY201100987 T CY 201100987T CY 1124024 T1 CY1124024 T1 CY 1124024T1
Authority
CY
Cyprus
Prior art keywords
immunoproscollitins
ctla4
novel ctla4
novel
adhesins
Prior art date
Application number
CY20201100987T
Other languages
English (en)
Inventor
Gregory A. Lazar
Matthew J. Bernett
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of CY1124024T1 publication Critical patent/CY1124024T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Η παρούσα αίτηση αναφέρεται σε CTLA4-Ig προσκολλητίνες που στοχεύουν στις CD80 και CD86, και στη χρήση τους, συγκεκριμένα για θεραπευτικούς σκοπούς.
CY20201100987T 2010-02-19 2020-10-20 Νεες ctla4-ig ανοσοπροσκολλητινες CY1124024T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30631110P 2010-02-19 2010-02-19
US33480610P 2010-05-14 2010-05-14
US41230910P 2010-11-10 2010-11-10
PCT/US2011/025747 WO2011103584A2 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins
EP11727563.6A EP2536745B1 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins

Publications (1)

Publication Number Publication Date
CY1124024T1 true CY1124024T1 (el) 2022-03-24

Family

ID=44483626

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100794T CY1118001T1 (el) 2010-02-19 2016-08-10 Νεες ctla4-ig προσκολλητινες
CY20201100987T CY1124024T1 (el) 2010-02-19 2020-10-20 Νεες ctla4-ig ανοσοπροσκολλητινες

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100794T CY1118001T1 (el) 2010-02-19 2016-08-10 Νεες ctla4-ig προσκολλητινες

Country Status (19)

Country Link
US (7) US8329867B2 (el)
EP (2) EP3053932B1 (el)
JP (1) JP5705242B2 (el)
KR (1) KR101926663B1 (el)
CN (3) CN113372451A (el)
AU (2) AU2011217770B2 (el)
CA (1) CA2790487C (el)
CY (2) CY1118001T1 (el)
DK (2) DK2536745T3 (el)
ES (2) ES2586579T3 (el)
HR (2) HRP20160938T1 (el)
HU (2) HUE050768T2 (el)
LT (2) LT3053932T (el)
PL (2) PL2536745T3 (el)
PT (1) PT3053932T (el)
RS (1) RS61136B1 (el)
SI (2) SI2536745T1 (el)
SM (1) SMT201600289B (el)
WO (1) WO2011103584A2 (el)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
JP5624276B2 (ja) 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
TR201808046T4 (tr) 2008-04-11 2018-06-21 Chugai Pharmaceutical Co Ltd İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR101791430B1 (ko) 2009-11-30 2017-10-30 얀센 바이오테크 인코포레이티드 이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
DK2536745T3 (en) 2010-02-19 2016-08-22 Xencor Inc NOVEL CTLA4-IG immunoadhesins
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
RU2642318C2 (ru) 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
KR101536151B1 (ko) * 2012-01-31 2015-07-14 서울대학교산학협력단 새로운 ＣＴＬＡ-４ＩｇＧ 융합 단백질
US9758566B2 (en) * 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
KR102133060B1 (ko) * 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
EP2855533A4 (en) * 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
MX2015014017A (es) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Variante de la region fc.
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3017048A4 (en) * 2013-07-01 2017-05-17 University of Maryland, College Park Fc coupled compositions and methods of their use
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-PD1 antibodies and their uses as drugs and for diagnosis
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
NZ728688A (en) 2014-07-22 2023-06-30 Cb Therapeutics Inc Anti-pd-1 antibodies
SG11201700687TA (en) 2014-08-05 2017-02-27 Cb Therapeutics Inc Anti-pd-l1 antibodies
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3461337A1 (en) 2015-05-06 2019-04-03 Snipr Technologies Limited Altering microbial populations & modifying microbiota
FR3035879A1 (fr) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
TWI733685B (zh) * 2015-07-23 2021-07-21 德商包林格因蓋爾漢國際股份有限公司 靶向il-23a與b細胞活化因子(baff)之化合物及其用途
EP3370733B1 (en) 2015-11-02 2021-07-14 Board of Regents, The University of Texas System Methods of cd40 activation and immune checkpoint blockade
CN108884159A (zh) 2015-11-07 2018-11-23 茂体外尔公司 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
BR112018072286A2 (pt) 2016-04-29 2019-02-12 Yale University medida direcionada de atividade transcricional relacionada a receptores de hormônios
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
US11395838B2 (en) 2016-09-27 2022-07-26 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
CN116672456A (zh) 2016-10-12 2023-09-01 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
US11883430B2 (en) 2016-11-09 2024-01-30 Musc Foundation For Research Development CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
EP3586136B1 (en) 2017-02-24 2023-11-08 Board Of Regents, The University Of Texas System Assay for detection of early stage pancreatic cancer
US12116412B2 (en) 2017-03-03 2024-10-15 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
CA3054068A1 (en) * 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
SG10201913206RA (en) 2017-05-25 2020-02-27 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
CN110719799A (zh) 2017-06-09 2020-01-21 俄勒冈州普罗维登斯健康与服务部 Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
KR102631281B1 (ko) * 2017-08-10 2024-01-30 그리폴스 다이어그노스틱 솔루션즈 인크. 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트
KR20230020022A (ko) * 2017-10-10 2023-02-09 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US20210179687A1 (en) 2017-11-07 2021-06-17 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
US12097257B2 (en) 2018-03-05 2024-09-24 New York University Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202009504YA (en) 2018-03-25 2020-10-29 Snipr Biome Aps Treating & preventing microbial infections
CN112088000A (zh) 2018-03-27 2020-12-15 得克萨斯州大学系统董事会 具有针对携带her2外显子19突变之癌细胞的抗肿瘤活性的化合物
WO2019224842A1 (en) * 2018-05-25 2019-11-28 Dr. Reddy's Laboratories Ltd. Stable fusion protein formulation
WO2020088645A1 (en) * 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
WO2020106621A1 (en) 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3887518A2 (en) 2018-11-28 2021-10-06 Board of Regents, The University of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
AU2020268199A1 (en) 2019-05-09 2021-11-18 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法
BR112021026410A2 (pt) 2019-07-01 2022-02-08 Tonix Pharma Ltd Anticorpos anti-cd154 e usos dos mesmos
AU2020333967A1 (en) * 2019-08-22 2022-03-17 Cidara Therapeutics, Inc. Variant Fc domains and uses thereof
US20220380765A1 (en) 2019-11-02 2022-12-01 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
AU2021205337A1 (en) 2020-01-10 2022-07-21 Modernatx, Inc. Methods of making tolerogenic dendritic cells
WO2021155267A2 (en) 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023526416A (ja) 2020-05-21 2023-06-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｖｇｌｌ１特異性を有するｔ細胞受容体およびその使用法
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
US20230051406A1 (en) 2020-11-13 2023-02-16 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US20220162288A1 (en) 2020-11-25 2022-05-26 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2022159492A1 (en) 2021-01-19 2022-07-28 William Marsh Rice University Bone-specific delivery of polypeptides
EP4351595A1 (en) 2021-06-07 2024-04-17 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
AU2022291395A1 (en) 2021-06-11 2024-01-04 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
JP2024531910A (ja) 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
WO2023060136A1 (en) 2021-10-05 2023-04-13 Cytovia Therapeutics, Llc Natural killer cells and methods of use thereof
MX2024004365A (es) 2021-10-20 2024-04-25 Takeda Pharmaceuticals Co Composiciones que actuan sobre el antigeno de maduracion de linfocitos b (bcma) y metodos de uso de las mismas.
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
AU2022378755A1 (en) * 2021-10-28 2024-06-06 Monash University Variant ctla4 proteins
AU2022410059A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CN1443850A (zh) * 2002-03-08 2003-09-24 重庆立丹(集团)药业科技开发有限公司 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CN101519451B (zh) * 2005-04-05 2011-05-25 上海中信国健药业股份有限公司 重组人sCTLA4-Ig融合蛋白基因及其药物组合物
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
MX2010004883A (es) * 2007-11-01 2010-11-10 Perseid Therapeutics Llc Polipeptidos y acidos nucleicos inmunosupresores.
DK2235059T3 (en) * 2007-12-26 2015-03-30 Xencor Inc FC-VERSIONS OF MODIFIED BINDING TO FcRn
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
DK2536745T3 (en) 2010-02-19 2016-08-22 Xencor Inc NOVEL CTLA4-IG immunoadhesins
US8642557B2 (en) * 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses

Also Published As

Publication number Publication date
US11352412B2 (en) 2022-06-07
DK3053932T3 (da) 2020-10-19
US9371397B2 (en) 2016-06-21
HUE050768T2 (hu) 2021-01-28
CN113372451A (zh) 2021-09-10
WO2011103584A2 (en) 2011-08-25
CN103038251B (zh) 2016-08-17
SMT201600289B (it) 2016-11-10
AU2016202816A1 (en) 2016-05-26
LT3053932T (lt) 2020-11-10
US20210230250A1 (en) 2021-07-29
EP3053932B1 (en) 2020-07-22
LT2536745T (lt) 2016-09-26
HRP20201614T1 (hr) 2020-12-11
KR20120120993A (ko) 2012-11-02
EP2536745B1 (en) 2016-05-11
ES2586579T3 (es) 2016-10-17
HRP20160938T1 (hr) 2016-10-07
CY1118001T1 (el) 2017-05-17
AU2016202816B2 (en) 2018-01-04
US11254727B2 (en) 2022-02-22
PL3053932T3 (pl) 2021-03-08
EP2536745A2 (en) 2012-12-26
US8629113B2 (en) 2014-01-14
SI3053932T1 (sl) 2021-01-29
CA2790487A1 (en) 2011-08-25
US10155800B2 (en) 2018-12-18
CA2790487C (en) 2020-10-06
AU2011217770A1 (en) 2012-09-06
JP2013520176A (ja) 2013-06-06
ES2826894T3 (es) 2021-05-19
US20140112924A1 (en) 2014-04-24
SI2536745T1 (sl) 2016-10-28
CN106432473A (zh) 2017-02-22
US20190127437A1 (en) 2019-05-02
WO2011103584A9 (en) 2012-08-16
WO2011103584A3 (en) 2012-07-12
DK2536745T3 (en) 2016-08-22
KR101926663B1 (ko) 2018-12-07
US20130089550A1 (en) 2013-04-11
US8329867B2 (en) 2012-12-11
CN106432473B (zh) 2021-04-02
US20160264643A1 (en) 2016-09-15
US20220348634A1 (en) 2022-11-03
JP5705242B2 (ja) 2015-04-22
PT3053932T (pt) 2020-10-21
HUE030100T2 (en) 2017-04-28
US20110287032A1 (en) 2011-11-24
EP3053932A1 (en) 2016-08-10
AU2011217770B2 (en) 2016-02-04
RS61136B1 (sr) 2020-12-31
PL2536745T3 (pl) 2017-01-31
CN103038251A (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
CY1124024T1 (el) Νεες ctla4-ig ανοσοπροσκολλητινες
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
CY1120374T1 (el) Ενεργοποιητες κινασων πυρουβικου για χρηση σε θεραπεια
CL2012003385A1 (es) Tratamiento para la incontinencia.
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CL2011000482S1 (es) Aplicador para cuidado oral.
EA201791843A2 (ru) Способы повышения эффективности folr1 терапии рака
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY34454A (es) Moléculas de unión para bcma y cd3
UY34885A (es) Proteínas de unión anti-mesotelina
UY34411A (es) Inmunoenlazantes dirigidos contra esclerostina
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
EA201400178A1 (ru) Лечение рака молочной железы
UA112086C2 (uk) Гербіцидні композиції, що включають хлорацетаміди
UY34582A (es) Anticuerpos anti-cxcr3
JO3755B1 (ar) تركيبات تستوستيرون
CY1118968T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CY1118912T1 (el) Πηκτωματουμενο κολλαγονο και μεσο για τη διαθεση αυτου
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY34286A (es) Diagnóstico de vacuna mejorado
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης